The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression

Pharmacogenomics Journal

Volumn 5, Issue 1, 2005, Pages 49-53

  Szegedi, Armin ^a   Rujescu, D ^b   Tadic, A ^c   Muller M J ^c   Kohnen, R ^d   Stassen, H H ^e   Dahmen, N ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d IMEREM   (Germany)

^e UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Antidepressant; COMT; Mirtazapine; Paroxetine; Pharmacogenetics; Response

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPAMINE; METHIONINE; MIRTAZAPINE; NORADRENALIN; PAROXETINE; VALINE;

ADULT; ARTICLE; CATECHOLAMINERGIC SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ENZYME DEGRADATION; ENZYME METABOLISM; ENZYME POLYMORPHISM; FEMALE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAMILTON SCALE; HETEROZYGOTE; HUMAN; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY;

ADULT; CATECHOL O-METHYLTRANSFERASE; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; METHIONINE; MIANSERIN; MIDDLE AGED; PAROXETINE; POLYMORPHISM, GENETIC; TIME FACTORS; VALINE;

EID: 13544263559     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500289     Document Type: Article

References (16)

1. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3: 508-511.
2. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000; 20: 105-107.
3. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11: 215-219.
4. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23: 587-590.
5. Serretti A, Zanardi R, Cusin C, Rossini D, Lorenzi C, Smeraldi E. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur Neuropsychopharmacol 2001; 11: 375-380.
6. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 2001; 6: 586-592.
7. Muller DJ, Schulze TG, Macciardi F, Ohlraun S, Gross MM, Scherk H et al. Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter. Pharmacopsychiatry 2002; 35: 157-158.
8. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998; 51: 267-285.
9. Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000; 355: 911-918.
10. Mannisto PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 1999; 51: 593-628.
11. Lee MS, Lyoo CH, Ulmanen I, Syvanen AC, Rinne JO. Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease. Neurosci Lett 2001; 298 131-134.
12. Chong DJ, Suchowersky O, Szumlanski C, Weinshilboum RM, Brant R, Campbell NR. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease. Clin Neuropharmacol 2000; 23: 143-148.
13. Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001; 7: 249-264.
14. Charney DS, Heninger GR, Sternberg DE, Redmond DE, Leckman JF, Maas JW et al. Presynaptic adrenergic receptor sensitivity in depression. The effect of long-term desipramine treatment. Arch Gen Psychiatry 1981; 38: 1334-1340.
15. Linner L, Arborelius L, Nomikos GG, Bertilsson L, Svensson TH. Locus coeruleus neuronal activity and noradrenaline availability in the frontal cortex of rats chronically treated with imipramine: effect of alpha 2-adrenoceptor blockade. Biol Psychiatry 1999; 46: 766-774.
16. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000; 61: 656-663.